Sana Biotechnology, Inc. (NASDAQ:SANA – Get Ranking) noticed an uptick in investing volume on Friday . 34,463 shares modified fingers throughout investing, a drop of 98% from the earlier session’s quantity of 1,441,293 shares.The inventory very last traded at $6.54 and experienced earlier closed at $6.43.
Independently, Morgan Stanley diminished their price target on shares of Sana Biotechnology to $15.00 and set an “overweight” rating on the inventory in a analysis report on Tuesday, Could 17th.
The enterprise has a market place cap of $1.23 billion, a PE ratio of -5.71 and a beta of 1.46. The enterprise has a 50-day uncomplicated shifting typical of $5.69 and a 200-day simple relocating ordinary of $7.95.
Sana Biotechnology (NASDAQ:SANA – Get Ranking) past declared its earnings outcomes on Tuesday, Could 10th. The enterprise claimed ($.47) earnings per share (EPS) for the quarter, lacking analysts’ consensus estimates of ($.38) by ($.09). As a group, equities investigation analysts predict that Sana Biotechnology, Inc. will post -1.4 EPS for the existing fiscal year.
A range of hedge money and other institutional traders have lately made adjustments to their positions in SANA. Allspring Worldwide Investments Holdings LLC obtained a new posture in shares of Sana Biotechnology in the fourth quarter worth $73,000. XTX Topco Ltd obtained a new position in shares of Sana Biotechnology in the 1st quarter worthy of $86,000. Hsbc Holdings PLC acquired a new situation in shares of Sana Biotechnology in the initially quarter worthy of $90,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new posture in shares of Sana Biotechnology in the fourth quarter worthy of $131,000. At last, Arizona Point out Retirement Process acquired a new position in shares of Sana Biotechnology in the fourth quarter value $157,000. 57.38% of the inventory is currently owned by institutional investors.
Sana Biotechnology Corporation Profile (NASDAQ:SANA)
Sana Biotechnology, Inc, a biotechnology firm, focuses on making use of engineered cells as medications. The enterprise develops ex vivo and in vivo mobile engineering platforms for many therapeutic areas with unmet treatment wants, which include oncology, diabetes, central anxious process diseases, cardiovascular ailments, genetic ailments, and other individuals.
Get News & Scores for Sana Biotechnology Every day – Enter your e mail deal with down below to receive a concise day by day summary of the newest news and analysts’ scores for Sana Biotechnology and connected firms with MarketBeat.com’s Cost-free day-to-day electronic mail newsletter.